OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Brown Discusses Acalabrutinib in CLL

February 28th 2017

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the novel agent acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Fanale on Clinical Trials for T-Cell Lymphoma

February 28th 2017

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

Dr. Choueiri on the Role of Traditional Agents in Kidney Cancer

February 27th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of traditional agents in the treatment of patients with kidney cancer.

Dr. Mauro on Current and Emerging Agents for MPNs

February 25th 2017

Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses some of the emerging and current therapies for patients with myeloproliferative neoplasms (MPNs).

Dr. Mesa on Incorporating MPN Guidelines into Clinical Practice

February 25th 2017

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.

Dr. Petrylak on Trial of Atezolizumab in Urothelial Carcinoma

February 24th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).

Dr. Jain on PD-1 Expression in Nivolumab/Ibrutinib Combination in CLL

February 24th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).

Dr. Jones on Studying Venetoclax in R/R CLL

February 24th 2017

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

Dr. Burke on Findings of GOYA Study for Diffuse Large B-Cell Lymphoma

February 24th 2017

John M. Burke, MD, Rocky Mountain Cancer Centers, discusses the significant findings of the phase III GOYA study investigating obinutuzumab (Gazyva) plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Dr. Oh on the Sequencing of New Therapies for Prostate Cancer

February 24th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).

Dr. Linehan on Genes With Predisposition to Kidney Cancer

February 24th 2017

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses genetic conditions with predisposition for patients with kidney cancer.

Dr. Tagawa on Updated Results of TAXYNERGY Trial in Prostate Cancer

February 23rd 2017

Scott T. Tagawa, MD, Weill Cornell Medicine, discusses the updated results of a prospective biomarker anaylsis from the TAXYNERGY trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Drake on Promise of Immunotherapy Combinations in Genitourinary Cancers

February 23rd 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.

Dr. Saad on Apalutamide Combination for Castration-Resistant Prostate Cancer

February 23rd 2017

Fred Saad, MD, University of Montreal Hospital Centers, discusses the safety and efficacy of the apalutamide combination for patients with metastatic castration-resistant prostate cancer.

Dr. Jones on the Safety of Venetoclax in CLL

February 23rd 2017

Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Morris on Challenges of Radium-223 Treatment in Prostate Cancer

February 23rd 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with radium-223 treatment in prostate cancer.

Dr. McDermott on IMmotion150 Trial in RCC

February 22nd 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).

Dr. Oh Discusses the Role of Chemotherapy in Prostate Cancer

February 22nd 2017

William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.

Dr. White on CNS Metastases in HER2+ Breast Cancer

February 22nd 2017

Julia White, MD, The Ohio State University Comprehensive Cancer Center, discusses brain metastases in patients with HER2-positive breast cancer.

Dr. Saad on Radium-223 for Prostate Cancer

February 22nd 2017

Fred Saad, MD, professor and chief of Urology, Director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses radium-223 dichloride (Xofigo) for patients with prostate cancer.